<DOC>
	<DOCNO>NCT00250029</DOCNO>
	<brief_summary>1.1 To collect pathological tumor specimens patient metastatic colorectal cancer prospective fashion correlative study response oxaliplatin base chemotherapy regimen . 1.2 To determine gene expression profile predict response oxaliplatin base chemotherapy regimen cohort patient .</brief_summary>
	<brief_title>Gene Expression Analysis Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen</brief_title>
	<detailed_description>This single-arm , non-randomized trial oxaliplatin capecitabine . Patients place study utilize chemotherapy regimen enter study . Those patient treat accord clinical study enter . For patient another clinical trial , treatment outline follow .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Diseases</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>All patient , &gt; 18 year age , metastatic/recurrent colorectal cancer eligible . Patients must life expectancy least 12 week . Patients must Zubrod performance status 02 . Patients must sign informed consent . Patients adequate bone marrow function define absolute peripheral granulocyte count &gt; 1,500 cells/mm3 platelet count &gt; 100,000/mm3 absence regular red blood cell transfusion requirement . Patients adequate hepatic function total bilirubin &lt; 2 mg/dl SGOT SGPT &lt; two time upper limit normal , adequate renal function define serum creatinine &lt; 1.5 x upper limit normal . The patient must agree biopsy sample tumor correlative study . The patient appropriate candidate oxaliplatin/capecitabine base chemotherapy . The patient must measurable disease . Patients symptomatic brain metastasis exclude study . Pregnant woman nurse mother eligible trial . Patients child bear potential must use adequate contraception . Patients may receive concurrent chemotherapy radiation therapy trial . Patients severe medical problem uncontrolled diabetes mellitus cardiovascular disease active infection eligible trial . Patients may receive oxaliplatin previously . Patients prior unanticipated severe reaction fluoropyrimidine therapy , know dihydropyrimidine dehydrogenase ( DPD ) deficiency , know hypersensitivity platinum compound component study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Pilot Study</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>